Showing results (311-320 of 320) with videos related to
Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2000
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responsesE Jäger, Y Nagata, S Gnjatic, et al.British Journal of Cancer|March 17, 2005
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFRC Panousis, V M Rayzman, T G Johns, et al.Cancer Research|June 5, 2001
Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenograftsF T Lee, A Rigopoulos, C Hall, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinomaC R Divgi, N H Bander, A M Scott, et al.Cancer Immunology, Immunotherapy : CII|November 17, 2010
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondC M Britten, S Janetzki, S H van der Burg, et al.Proceedings of the National Academy of Sciences of the United States of America|January 21, 1997
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamilyJ K Heath, S J White, C N Johnstone, et al.The Journal of Biological Chemistry|October 11, 1996
Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epitheliumB Catimel, G Ritter, S Welt, et al.Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.Pageof 32